Showing results (351-360 of 371) with videos related to

Sort By:
Pageof 38
Clinical Neuropharmacology|September 29, 2001
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopaJ M Rabey, I Sagi, M Huberman, et al.
NPJ Precision Oncology|April 26, 2022
Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomasNathan D Seligson, Joy Tang, Dexter X Jin, et al.
Frontiers in Pharmacology|January 23, 2024
CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantationNathan D Seligson, Xunjie Zhang, Mark C Zemanek, et al.
Pharmacogenomics|July 29, 2025
From bench to bedside: a spotlight on pharmacogenomics at Nemours Children's HealthKelsey J Cook, Nathan D Seligson, Benjamin Q Duong, et al.
Cancers|November 9, 2024
Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566Ryan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 11, 2001
Consensus statement on the role of acute dopaminergic challenge in Parkinson's diseaseA Albanese, U Bonuccelli, C Brefel, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 1, 1994
Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of actionA Achiron, R Gilad, R Margalit, et al.
Cancers|April 3, 2021
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical ImplementationRyan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Haematologica|March 2, 2023
PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplantMelissa Thomas, Junan Li, Kevan King, et al.
Experimental Neurology|January 31, 2012
Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's diseaseO Sadan, N Shemesh, R Barzilay, et al.
Pageof 38